Compare TFX & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TFX | LQDA |
|---|---|---|
| Founded | 1943 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.5B |
| IPO Year | 1994 | 2020 |
| Metric | TFX | LQDA |
|---|---|---|
| Price | $134.98 | $90.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | ★ $138.75 | $41.00 |
| AVG Volume (30 Days) | 468.9K | ★ 1.3M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | N/A | ★ 51.81 |
| EPS | ★ 2.08 | 0.52 |
| Revenue | ★ $1,992,713,000.00 | $158,320,000.00 |
| Revenue This Year | $15.97 | $278.87 |
| Revenue Next Year | $5.15 | $57.13 |
| P/E Ratio | ★ N/A | $171.96 |
| Revenue Growth | N/A | ★ 1031.18 |
| 52 Week Low | $100.18 | $19.90 |
| 52 Week High | $145.00 | $91.57 |
| Indicator | TFX | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 58.51 | 63.70 |
| Support Level | $121.29 | $31.99 |
| Resistance Level | N/A | $91.10 |
| Average True Range (ATR) | 4.65 | 5.03 |
| MACD | 0.44 | -0.02 |
| Stochastic Oscillator | 59.18 | 85.26 |
Teleflex Inc is a provider of medical technology products focused on enhancing clinical benefits, improving patient and provider safety and reducing total procedural costs. It designs, develops, manufactures and supply medical devices used by hospitals and healthcare providers supporting high-acuity emergent procedures. The company has three reportable segments: Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). It derives maximum revenue from Americas. Its products includes: Anaesthesia, Emergency Medicine, Interventional Cardiology/Radiology, Interventional Urology - UroLift System, Surgery, Urology, and Vascular Access.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.